Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years

NCT00219752 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG: Imatinib mesylate 400 mg

Sponsor

Poitiers University Hospital

Collaborators

[object Object]